News | February 18, 2025
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Offers affordable, high-quality solutions for diabetes care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Plans underway to expand screening capacity by 50% for greater accessibility
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Subscribe To Our Newsletter & Stay Updated
